SEATTLE, March 26, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global custom recombinant protein production services market is estimated to be valued at US$ 2,338.32 million in 2020 and is projected to exhibit a CAGR of 11.2% over the forecast period (2020 – 2027).
Key Trends and Analysis of the Custom Recombinant Protein Production Services Market:
Key trends in the market include increasing demand for recombinant proteins, technological advancements in the production of recombinant proteins, and increasing funding in life sciences.
Market players are actively investing in research and development to understand the normal functionality of cell and to identify the changes that lead to protein dysfunction during diseases, which is fueling growth of the market. Moreover, increasing funding in life sciences is expected to boost the market growth. For instance, in 2019, The Oxford Protein Production Facility-UK (OPPF-UK) in the U.K. received additional funding of US$ 3 million from Laboratory of Molecular Biology (MRC) to provide a range of highly specialized technologies incorporating robotic systems, for high throughput expression, purification & crystallization of recombinant proteins. Similarly, the government of Sweden is focused on investing in life sciences research infrastructure and is participating in 73 research projects with a total funding of US$ 57 million.
Moreover, key players operating in the market are focused on launching and expanding its recombinant protein production services and capability, which is expected to boost the market growth. For instance, in 2020, Lonza Company launched GSv9 Media and Feeds that provide a fully integrated solution specifically designed to optimize recombinant protein production. With the launch of this production capacity, the company has expanded its cell culture media portfolio.
Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/2737
However, high cost of protein expression services used for R&D activities in the fields of biotechnology and pharmaceutical industry is a major factor restraining the market growth. For instance, the average cost of recombinant protein produced is around US$ 11,000-17,000/mg in E. coli expression system.
Key Market Takeaways:
The custom recombinant protein production services market is expected to exhibit a CAGR of 11.2% during the forecast period (2020 – 2027). This is owing to factors such as high demand for recombinant proteins, technological advancements in the production of recombinant proteins, increasing funding in life sciences, and launch of novel services. For instance, in 2017, GenScript launched its custom rabbit monoclonal antibody (mAb) service, MonoRab, as part of the integrated premium antibody service portfolio.
Market growth is also attributed to approval and launch of novel products. For instance, in 2016, GenScript launched CRISPR-based Yeast Genome Editing Service with novel λ Red-CRISPR/Cas9 technology, thus making a CRISPR-based custom yeast cell line editing service commercially available.
Competitive Landscape:
Key players in the market are focused on adopting collaboration and acquisition strategies to enhance their product portfolio, which in turn is expected to propel the market growth over the forecast period. For instance, in 2017, Crown Bioscience collaborated with Shanghai Model Organisms Center (SMOC) to exclusively license and commercialize SMOC’s comprehensive collection of genetically engineered models, including transgenic and reporter models for oncology, cardiovascular, and immunology research. Thus, the products will be available for international clients for custom model generation.
Key players operating in the global custom recombinant protein production services market include GenScript Biotech Corporation, Applied Biological Materials Inc., Eurofins Pharma Discovery Services, Abgent, OriGene Technologies, Inc., Crown Bioscience, Inc., BPS Bioscience, Inc., ProteoGenix, Kempbio, Inc., Novoprotein, Premas Biotech, Trenzyme GmbH, Atum, Novus Biologicals, LLC, Icosagen AS, LakePharma, Inc., Proteos, Inc., Aldevron, Sino Biological Inc, and SignalChem Lifesciences Corporation
Buy-Now this Research Report for detailed market insights @ https://www.coherentmarketinsights.com/insight/buy-now/2737
Market Segmentation:
- Global Custom Recombinant Protein Production Services Market, By Expression System:
- Mammalian
- Bacteria
- Insect
- Yeast
- Others
- Global Custom Recombinant Protein Production Services, By End User:
- Research Institutes
- Biotechnology and Pharmaceutical Companies
- Contract Research Organizations
- Others
- Global Custom Recombinant Protein Production Services Market, By Region:
- North America
- By Country:
- U.S.
- Canada
- By Country:
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country:
- Europe
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- By Country:
- Asia Pacific
- By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Country:
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Country:
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Country/Region:
- North America
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.